Literature DB >> 15184629

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

J A Prince1, H Zetterberg, N Andreasen, J Marcusson, K Blennow.   

Abstract

The epsilon4 allele of APOE is a risk factor for Alzheimer disease (AD). By analysis of a large cohort of AD patients (n = 563) and control subjects (n = 118), it is shown that the epsilon4 allele is strongly associated with reduced CSF levels of beta-amyloid (1-42) (Abeta42) in both AD (p < 10(-9)) and control (p = 0.0012) populations. As no associations of APOE variants with other indexes of AD severity were observed, this effect may reflect a fundamental involvement of ApoE in Abeta metabolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184629     DOI: 10.1212/01.wnl.0000128088.08695.05

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  49 in total

Review 1.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

2.  CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

Authors:  A Siderowf; S X Xie; H Hurtig; D Weintraub; J Duda; A Chen-Plotkin; L M Shaw; V Van Deerlin; J Q Trojanowski; C Clark
Journal:  Neurology       Date:  2010-08-18       Impact factor: 9.910

3.  Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta 1-42 and plasma apolipoprotein levels.

Authors:  Hagit Katzov; Anna M Bennet; Kina Höglund; Björn Wiman; Dieter Lütjohann; Anthony J Brookes; Niels Andreasen; Kaj Blennow; Ulf De Faire; Jonathan A Prince
Journal:  J Hum Genet       Date:  2005-12-22       Impact factor: 3.172

4.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

Authors:  Miroslaw Brys; Elizabeth Pirraglia; Kenneth Rich; Sindre Rolstad; Lisa Mosconi; Remigiusz Switalski; Lidia Glodzik-Sobanska; Susan De Santi; Ray Zinkowski; Pankaj Mehta; Domenico Pratico; Leslie A Saint Louis; Anders Wallin; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-09-24       Impact factor: 4.673

Review 5.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

6.  BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.

Authors:  Boris Decourt; Amanda Gonzales; Thomas G Beach; Michael Malek-Ahmadi; Aaron Walker; Lucia Sue; Douglas G Walker; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2013-03       Impact factor: 3.498

Review 7.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

8.  Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients.

Authors:  Saila Vepsäläinen; Seppo Helisalmi; Anne M Koivisto; Toni Tapaninen; Mikko Hiltunen; Hilkka Soininen
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

9.  Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

Authors:  John S K Kauwe; Jun Wang; Kevin Mayo; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  Neurogenetics       Date:  2008-09-24       Impact factor: 2.660

10.  A survey of ABCA1 sequence variation confirms association with dementia.

Authors:  Chandra A Reynolds; Mun-Gwan Hong; Ulrika K Eriksson; Kaj Blennow; Anna M Bennet; Boo Johansson; Bo Malmberg; Stig Berg; Fredrik Wiklund; Margaret Gatz; Nancy L Pedersen; Jonathan A Prince
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.